Literature DB >> 30417922

Infiltrated M2 tumour-associated macrophages in the stroma promote metastasis and poor survival in oesophageal squamous cell carcinoma.

Jian Zhou1,2,3, Shutao Zheng2,4, Tao Liu4,2, Qing Liu2,4, Yumei Chen1,4, Rong Ma1,4, Doudou Tan1,2, Xiaomei Lu2,5.   

Abstract

Although M2 tumour-associated macrophages (M2 TAMs) have been shown to be associated with the progression and metastasis of breast cancer, their role in oesophageal squamous cell carcinoma (ESCC) remains less well understood. Therefore, to understand the clinicopathological significance of infiltrated M2 TAMs in ESCC, statistical analysis was performed after immunohistochemical evaluation of CD163 expression, a well-accepted surface marker of M2 TAMs in ESCC. To gain insight into the effect of M2 TAMs, ESCC cell lines Eca109 and KYSE150 cells were co-cultured with M2 TAMs artificially induced from THP-1 cells. The variations in the proliferation, migration and invasion were assessed using the MTT, wound-healing and Transwell assays, respectively. The variation in the typical biomarkers of the epithelial-mesenchymal transition (EMT) was evaluated using western blotting. Infiltrated M2 TAMs were confirmed to predominate in the stroma of ESCC relative to normal controls. Moreover, it turned out that M2 TAMs were shown to promote the migration and invasion of ESCC cells but not proliferation. Furthermore, M2 TAMs were observed to induce EMT in ESCC cells. Together, our results showed that infiltrated M2 TAMs in the stroma is a feature accompanying ESCC metastasis and that M2 TAMs can promote the migration and invasion, but not proliferation, of ESCC cells, thereby inducing EMT. Thus, M2 TAMs could be an alternative therapeutic target in ESCC.

Entities:  

Mesh:

Year:  2018        PMID: 30417922     DOI: 10.14670/HH-18-061

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  2 in total

1.  A Novel Autophagy-Related Long Non-Coding RNA Signature to Predict Prognosis and Therapeutic Response in Esophageal Squamous Cell Carcinoma.

Authors:  Xiaobo Shi; Xiaoxiao Liu; Shupei Pan; Yue Ke; Yuxing Li; Wei Guo; Yuchen Wang; Qinli Ruan; Xiaozhi Zhang; Hongbing Ma
Journal:  Int J Gen Med       Date:  2021-11-16

Review 2.  Targeting Strategies for Aberrant Lipid Metabolism Reprogramming and the Immune Microenvironment in Esophageal Cancer: A Review.

Authors:  Meng-Ying Cui; Xing Yi; Zhen-Zhen Cao; Dan-Xia Zhu; Jun Wu
Journal:  J Oncol       Date:  2022-09-05       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.